Mavyret is a medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is an all-oral, pan-genotypic treatment, meaning it can be used to treat all genotypes of hepatitis C without the need for interferon or ribavirin [2][3]. The active ingredients in Mavyret are glecaprevir and pibrentasvir [1].
How is Mavyret administered?
Mavyret is taken orally as tablets [1]. The recommended dosage is three tablets taken once daily with food [4].
What types of hepatitis C can Mavyret treat?
Mavyret is indicated for the treatment of chronic hepatitis C virus infection in adults across all major genotypes (GT1-6) [1][2]. It is approved for patients who have not been treated previously, as well as for those who have been treated with other regimens and failed [2][4]. This includes patients with compensated cirrhosis [2].
What is the efficacy of Mavyret?
Clinical trials have shown Mavyret to be highly effective, with sustained virologic response (SVR12) rates, which indicate a cure, generally exceeding 90% across different genotypes and patient populations [2][3]. For instance, in the EXPEDITION-4 trial, Mavyret achieved a 92% SVR12 rate in patients with genotype 1, 4, 5, or 6 HCV infection [3]. In the EXPEDITION-5 trial, it achieved a 96% SVR12 rate in patients with genotype 2 HCV infection [3].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1][4]. Other reported side effects can include nausea, diarrhea, and insomnia [4]. Patients are advised to report any persistent or bothersome side effects to their healthcare provider [1].
How long is the treatment duration for Mavyret?
The duration of Mavyret treatment depends on the individual patient's history and genotype [2][4]. It can be as short as eight weeks for treatment-naïve patients with genotypes 1, 2, 3, 4, 5, or 6, without cirrhosis [4]. For some patients, including those with prior treatment experience or compensated cirrhosis, the treatment duration may be extended to 16 weeks [4].
What are the contraindications for Mavyret?
Mavyret should not be taken by individuals who are taking certain medications that may interact with its components, such as certain antiretrovirals, antiepileptics, and St. John's wort [1]. It is also contraindicated in patients with severe hepatic impairment [1].
What is the mechanism of action of Mavyret?
Mavyret is a combination therapy that targets multiple stages of the HCV life cycle [2]. Glecaprevir is an NS3/4A protease inhibitor, which blocks an enzyme essential for viral replication [2]. Pibrentasvir is an NS5A inhibitor, which blocks another protein required for viral replication and assembly [2]. By inhibiting these targets, Mavyret effectively prevents the virus from multiplying [2].
When does Mavyret patent exclusivity expire?
Information regarding specific patent expiration dates for Mavyret can be found through resources like DrugPatentWatch.com [5]. Patent protection for drugs like Mavyret is crucial for their market exclusivity, influencing the availability of generic versions [5].
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie Inc. [1].
How does Mavyret compare to other hepatitis C treatments?
Mavyret's advantage lies in its pan-genotypic activity and shorter treatment durations for many patients, often eliminating the need for interferon and ribavirin, which can have significant side effects [2][3]. Other direct-acting antiviral (DAA) regimens are also available and may be preferred for specific patient profiles or genotypes, though Mavyret is noted for its broad applicability [2][3].
Where can I find more information about Mavyret?
Further details on Mavyret, including prescribing information and clinical trial data, can be obtained from healthcare providers or official drug information resources [1][2]. DrugPatentWatch.com also provides data on drug patents and exclusivity periods [5].
Sources
1. Mavyret Prescribing Information.
2. DrugPatentWatch.com.
3. Clinical trial results as published in peer-reviewed journals.
4. FDA approval documents for Mavyret.
5. DrugPatentWatch.com.